NervGen Wins FDA Breakthrough Therapy Designation for Spinal Cord Injury Drug as Phase 3 Enrollment Advances
Key Points
- NervGen received FDA Breakthrough Therapy designation for NVG-291 in chronic traumatic cervical motor-incomplete spinal cord injury.
- The decision followed FDA review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI study.
- The Phase 3 RESTORE trial is enrolling participants, with site activation continuing in the United States and Canada.
- The designation supports closer FDA engagement and potential review efficiencies, but it is not approval or a guarantee of approval.
NervGen Pharma Corp. (Nasdaq: NGEN) announced a regulatory milestone for NVG-291, its investigational treatment designed to promote nervous-system repair and functional recovery after spinal cord injury.
The designation applies to a specific population with chronic traumatic cervical motor-incomplete injuries—not all forms of spinal cord injury. It strengthens the program’s regulatory standing while leaving the pivotal clinical test ahead.
Earlier Results Support the Designation
According to NervGen, the chronic cohort of its Phase 1b/2a CONNECT SCI study showed substantial improvement on an endpoint measuring functional hand use.
The company said patient-reported assessments and blinded qualitative interviews also documented gains in everyday function and independence compared with placebo. NVG-291 was generally well tolerated, with no serious adverse events or treatment discontinuations reported in the cited cohort.
The announcement did not provide numerical treatment effects, statistical details or the cohort’s size, limiting investors’ ability to assess the magnitude of benefit from this update alone.
Phase 3 RESTORE Is the Main Clinical Catalyst
RESTORE is a randomized, double-blind, placebo-controlled registrational study expected to enroll approximately 150 adults across the United States and Canada.
Participants will receive NVG-291 or placebo through a once-daily subcutaneous injection for 12 weeks, followed by four weeks of observation. An optional 12-week open-label extension is planned.
The primary endpoint measures improvement in hand function using GRASSP Quantitative Prehension. Secondary measures and blinded interviews will examine functional independence and quality of life.
The announcement did not provide an enrollment-completion date or a topline-results timeline.
Investor Takeaway
Breakthrough Therapy designation provides more intensive FDA guidance, senior-level agency involvement and eligibility for rolling review and Priority Review if applicable requirements are met. It does not lower the evidence standard required for approval.fda+1
For NGEN investors, the milestone is meaningful regulatory progress, but the investment case still depends on RESTORE demonstrating a convincing benefit and an acceptable safety profile. Enrollment progress, trial execution and eventual Phase 3 results remain the key catalysts.
